Scholarlink

Background <p>Starting with the healthy liver, metabolic dysfunction-associated steatotic liver disease (MASLD) develops from simple steatosis and a&#xa0;necroinflammatory state (MASH) to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Extrahepatic manifestations include cardiovascular disease, extrahepatic tumors, and kidney disease. Once MASH is established, hepatic liver disease comes to the fore due to potential cirrhosis with portal hypertension and decompensation.</p> Aims <p>For this review, current studies, guidelines and meta-analyses were evaluated with regard to pathogenesis and therapeutic approaches.</p> Results <p>The focus of current therapeutic approaches for MASLD is on the early prevention (lifestyle modification) of hepatic and extrahepatic disorders. In a&#xa0;later stage, precision medicine approaches from personalized medications that target metabolism, body weight, and risk of malignancy are important. In MASH, anti-inflammatory and metabolic-modulating therapies address the resolution of MASH, the prophylaxis of fibrogenesis and MASH progression and/or the reduction of fibrosis. In cirrhosis and HCC, specific pharmacological therapies, locoregional treatments, liver resection, and liver transplantation should be considered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MASLD – Krankheitslast, Herausforderungen und neue Therapeutika

  • 期刊论文

  • 发表日期：

    2025年3月5日

查看全文
  • Elke Roeb

摘要

Background

Starting with the healthy liver, metabolic dysfunction-associated steatotic liver disease (MASLD) develops from simple steatosis and a necroinflammatory state (MASH) to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Extrahepatic manifestations include cardiovascular disease, extrahepatic tumors, and kidney disease. Once MASH is established, hepatic liver disease comes to the fore due to potential cirrhosis with portal hypertension and decompensation.

Aims

For this review, current studies, guidelines and meta-analyses were evaluated with regard to pathogenesis and therapeutic approaches.

Results

The focus of current therapeutic approaches for MASLD is on the early prevention (lifestyle modification) of hepatic and extrahepatic disorders. In a later stage, precision medicine approaches from personalized medications that target metabolism, body weight, and risk of malignancy are important. In MASH, anti-inflammatory and metabolic-modulating therapies address the resolution of MASH, the prophylaxis of fibrogenesis and MASH progression and/or the reduction of fibrosis. In cirrhosis and HCC, specific pharmacological therapies, locoregional treatments, liver resection, and liver transplantation should be considered.